<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117839">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02134769</url>
  </required_header>
  <id_info>
    <org_study_id>BIONECT-2014</org_study_id>
    <secondary_id>ZVK-Bionect</secondary_id>
    <nct_id>NCT02134769</nct_id>
  </id_info>
  <brief_title>Influence of Bionecteurs on Catheter-associated Infection</brief_title>
  <acronym>Bionect</acronym>
  <official_title>Incidence of Catheter-related Bloodstream Infections Using Bionecteur Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vygon GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bionecteur® is a protective non-touch applicator to ensure aseptic connection made by Vygon.
      However, there are no studies describing a positive effect of using Bionecteurs ® in regard
      to catheter-related bloodstream infections. In this study Bionecteur® will be used on
      central venous lines and arterial lines in postoperative patients of a 40-bed ICU. The
      incidence of catheter-related bloodstream infections will we compared to patients without
      inclusion of Bionecteur® devices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Prospective, randomised observational study

        -  Postsurgical patients in an anesthesiological ICU with ICU LOS  (LOS: length of stay) &gt;
           3 days

             -  Inclusion:

                ---- Age ≥ 18 years

                ---. demand of central venous and arterial line

                ---  written consent of patient and/or assignee

             -  Exclusion

                  -  Handicapped patients

                  -  patient with ICU LOS &lt; 3 days

        -  Study design

             1. Three days after admission to ICU blood cultures are drawn to exclude preexisting
                blood stream infection

             2. Patients in a bed with even number are assigned to Bionecteur® group. Control
                group (without using bionecteurs) are patients with an odd bed number.

             3. Biconecteurs® are connected to all lumens of the central catheter and to arterial
                catheter. Control group is treated without using Bionecteurs®. Handling of
                vascular catheters are performed as described in institutional guidelines in both
                groups.

             4. Catheter-related bloodstream infections are monitored by an independent person
                during ICU treatment

             5. The study will be finished ab discharge of ICU or removal of catheters.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of catheter-related bloodstream infections using Bionecteurs</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Stay in ICU</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine days in ICU with centrral venous catheter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No use of Bionecteur; handling according to institutional guideline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bionecteur</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of Bionecteur; handling according to institutional guideline</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bionecteur</intervention_name>
    <description>Using Bionecteur at each lumina of the catheter; handling according to institutional guideline</description>
    <arm_group_label>Bionecteur</arm_group_label>
    <other_name>bionector® company: Vygon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Length of Stay (LOS) in  ICU &gt; 3 days

          -  written consent by patient or notarial carers

          -  medical indication for central venous line/arterial line

        Exclusion Criteria:

          -  handicap

          -  LOS ICU &lt; 3 days

          -  no consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helene A Haeberle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helene A Haeberle, MD</last_name>
    <phone>+49 (0) 7071-298</phone>
    <phone_ext>6900</phone_ext>
    <email>helene.haeberle@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Rosenberger, Prof.</last_name>
    <phone>+49 (0) 7071-298</phone>
    <phone_ext>6622</phone_ext>
    <email>peter.rosenberger@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Helene A Haeberle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>catheter-related bloodstream infections</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Catheter-Related Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
